The osteoinductive properties of mesoporous silicate coated with osteostatin in a rabbit femur cavity defect model

Biomaterials

Volumn 31, Issue 33, 2010, Pages 8564-8573

  Trejo, Cynthia G ^a   Lozano, Daniel ^b   Manzano, Miguel ^c,d   Doadrio, Juan C ^c   Salinas, Antonio J ^c,d   Dapía, Sonia ^e   Gómez Barrena, Enrique ^b   Vallet Regí, María ^c,d   García Honduvilla, Natalio ^a   Buján, Julia ^a   Esbrit, Pedro ^b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^e Trabeculae Empresa de Base Tecnológica S L   (Spain)

Author keywords

Biocompatibility; Bone regeneration; Bone tissue engineering; Inducing osteogenesis; Osteostatine; SBA15 mesoporous silica

Indexed keywords

BIOCERAMICS; BIOCOMPATIBILITY; CELL CULTURE; COATED MATERIALS; DEFECTS; IMPLANTS (SURGICAL); MESOPOROUS MATERIALS; PEPTIDES; SILICA; SILICATES; TISSUE REGENERATION;

BONE REGENERATION; BONE TISSUE ENGINEERING; MESOPOROUS SILICA; OSTEOGENESIS; OSTEOSTATINE;

BONE;

OSTEOSTATIN; PARATHYROID HORMONE RELATED PROTEIN; SILICATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEFECT; BONE DEVELOPMENT; BONE REGENERATION; FEMUR; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RABBIT;

ORYCTOLAGUS CUNICULUS;

EID: 77957293429     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.07.103     Document Type: Article

References (38)

1. Bisello A., Horwitz M.J., Stewart A.F. Parathyroid hormone-related protein: an essential physiological regulator of adult bone mass. Endocrinology 2004, 145:3551-3553.
2. Miao D., He B., Jiang Y., Kobayashi T., Soroceanu M.A., Zhao J., et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 2005, 115:2402-2411.
3. Karaplis A.C., Vautour L. Parathyroid hormone-related peptide and the parathyroid hormone/parathyroid hormone-related peptide receptor in skeletal development. Curr Opin Nephrol Hypertens 1997, 6:308-313.
4. Rouffet J., Coxam V., Gaumet N., Barlet J.P. Preserved bone mass in ovariectomized rats treated with parathyroid-hormone-related peptide (1-34) and (107-111) fragments. Reprod Nutr Dev 1994, 34:473-481.
5. Stewart A.F., Cain R.L., Burr D.B., Jacob D., Turner C.H., Hock J.M. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 2000, 15:1517-1525.
6. Horwitz M.J., Tedesco M.B., Gundberg C., García-Ocaña A., Stewart A.F. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2003, 88:569-575.
7. Lozano D., de Castro L.F., Dapía S., Andrade-Zapata I., Manzarbeitia F., Álvarez-Arroyo M.V., et al. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia. Endocrinology 2009, 150:2027-2035.
8. Fenton A.J., Martin T.J., Nicholson G.C. Long-term culture of disaggregated rat osteoclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP [107-139]. J Cell Physiol 1993, 155:1-7.
9. Zheng M.H., McCaughan H.B., Papadimitriou J.M., Nicholson G.C., Wood D.J. Tartrate resistant acid phosphatase activity in rat cultured osteoclasts is inhibited by a carboxyl terminal peptide (osteostatin) from parathyroid hormone-related protein. J Cell Biochem 1994, 54:145-153.
10. Rihani-Basharat S., Lewinson D. PTHrP (107-111) inhibits in vivo resorption that was stimulated by PTHrP (1-34) when applied intermittently to neonatal mice. Calcif Tissue Int 1997, 61:426-428.
11. Cornish J., Callon K.E., Nicholson G.C., Reid I.R. Parathyroid hormone-related protein(107-139) inhibits bone resorption in vivo. Endocrinology 1997, 38:1299-1304.
12. Cuthbertson R.M., Kemp B.E., Barden J.A. Structure study of osteostatin PTHrP[Thr107](107-139). Biochim Biophys Acta 1999, 1432:64-72.
13. Guo R., Quarles L.D. Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. J Bone Miner Res 1997, 12:1009-1017.
14. Boileau G., Tenenhouse H.S., Desgroseillers L., Crine P. Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors. Biochem J 2001, 355:707-713.
15. Cornish J., Callon K.E., Lin C., Xiao C., Moseley J.M., Reid I.R. Stimulation of osteoblast proliferation by C-terminal fragments of parathyroid hormone-related protein. J Bone Miner Res 1999, 14:915-922.
16. de Gortázar A.R., Alonso V., Álvarez-Arroyo M.V., Esbrit P. Transient exposure to PTHrP (107-139) exerts anabolic effects through vascular endothelial growth factor receptor 2 in human osteoblastic cells in vitro. Calcif Tissue Int 2006, 79:360-369.
17. Lozano D., Manzano M., Doadrio J.C., Salinas A.J., Vallet-Regí M., Gómez-Barrena E., et al. Osteostatin-loaded bioceramics stimulate osteoblastic growth and differentiation. Acta Biomater 2010, 6:797-803.
18. 2+ through a receptor different from the type 1 PTH/PTHrP receptor in osteoblastic osteosarcoma UMR 106 cells. Endocrinology 2001, 142:2752-2759.
19. Guillén C., Martínez P., de Gortázar A.R., Martínez M.E., Esbrit P. Both N- and C-terminal domains of parathyroid hormone-related protein increase interleukin-6 by NF-κB activation in osteoblastic cells. J Biol Chem 2002, 277:28109-28117.
20. Alonso V., de Gortázar A.R., Ardura J.A., Andrade-Zapata I., Álvarez-Arroyo M.V., Esbrit P. Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2. J Cell Physiol 2008, 217:717-727.
21. de Castro L.F., Lozano D., Dapía S., Portal-Núñez S., Caeiro J.R., Gómez-Barrena E., et al. Role of the N- and C-terminal fragments of parathyroid hormone-related protein as putative therapies to improve bone regeneration under high glucocorticoid treatment. Tissue Eng Part A 2010, 16:1157-1168.
22. Ferguson C.M., Miclau T., Hu D., Alpern E., Helms J.A. Common molecular pathways in skeletal morphogenesis and repair. Ann NY Acad Sci 1998, 857:33-42.
23. Deschaseaux F., Sensébé L., Heymann D. Mechanisms of bone repair and regeneration. Trends Mol Med 2009, 15:417-429.
24. Walsh W.R., Sherman P., Howlett C.R., Sonnabend D.H., Ehrlich M.G. Fracture healing in a rat osteopenia model. Clin Orthop Relat Res 1997, 342:218-227.
25. Andreassen T.T., Ejersted C., Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 1999, 14:960-968.
26. Bostrom M.P., Gamradt S.C., Asnis P., Vickery B.H., Hill E., Avnur Z., et al. Parathyroid hormone-related protein analog RS-66271 is an effective therapy for impaired bone healing in rabbits on corticosteroid therapy. Bone 2000, 26:437-442.
27. Vallet-Regí M., Balas F., Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Ed 2007, 46:7548-7558.
28. Vallet-Regi M., Balas F., Colilla M., Manzano M. Bone-regenerative bioceramic implants with drug and protein controlled delivery capability. Prog Solid State Chem 2008, 36:163-191.
29. Manzano M., Vallet-Regí M. New developments in ordered mesoporous materials for drug delivery. J Mater Chem 2010, 20:5593-5604.
30. Zhao D., Hou Q., Fena J., Chmelka B.F., Stucky G.D. Non ionic triblock and star diblock copolymer and oligomeric surfactant synthesis of highly ordered, hydrothermally stable, mesoporous silica structures. J Am Chem Soc 1998, 120:6024-6036.
31. Schipani E., Maes C., Carmeliet G., Semenza G.L. Regulation of osteogenesis-angiogenesis coupling by HIFs and VEGF. J Bone Miner Res 2009, 24:1347-1353.
32. Keller H., Kneissel M. SOST is a target gene for PTH in bone. Bone 2005, 37:148-158.
33. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23:860-869.
34. Arrighi I., Mark S., Alvisi M., von Rechenberg B., Hubbell J.A., Schense J.C. Bone healing induced by local delivery of an engineered parathyroid hormone prodrug. Biomaterials 2009, 30:1763-1771.
35. Tsai C.H., Lin R.M., Ju C.P., Chern Lin J.H. Bioresorption behavior of tetracalcium phosphate-derived calcium phosphate cement implanted in femur of rabbits. Biomaterials 2008, 29:984-993.
36. Chau J.F.L., Leong W.F., Li B. Signaling pathways governing osteoblast proliferation, differentiation and function. Histol Histopath 2009, 24:1593-1606.
37. Rutten S., Nolte P.A., Korstjens C.M., Klein-Nulend J. Low-intensity pulsed ultrasound affects RUNX2 immunopositive osteogenic cells in delayed clinical fracture healing. Bone 2009, 45:862-869.
38. Jacobsen K.A., Al-Aql Z.S., Wan C., Fitch J.L., Stapleton S.N., Mason Z.D., et al. Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling. J Bone Miner Res 2008, 23:596-609.